| COVID-19 |
1 |
1 |
| Antiviral Agents |
0 |
0.99 |
| Patient Safety |
0 |
0.44 |
| HIV Infection |
0 |
0.43 |
| Biologic Therapy |
0 |
0.41 |
| Hospital |
0 |
0.32 |
| Monoclonal Antibody |
0 |
0.32 |
| Strep Throat |
0 |
0.32 |
| Protease Inhibitor |
0 |
0.31 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.26 |
| Adverse Effects |
0 |
0.22 |
| Clinical Research |
0 |
0.22 |
| Food and Drug Administration (FDA) |
0 |
0.98 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.22 |
| Pandemic |
0 |
0.97 |
| Proteases |
0 |
0.22 |
| Otolaryngology |
0 |
0.2 |
| Vaccines |
0 |
0.2 |
| Calcaneal |
0 |
0.11 |
| Clinician Health and Well-Being |
0 |
0.11 |
| Drug Development |
0 |
0.96 |
| Immunization |
0 |
0.11 |
| Massachusetts |
0 |
0.11 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.11 |
| Prescription Drugs |
0 |
0.11 |
| Preventive Medicine |
0 |
0.11 |
| Tennessee |
0 |
0.11 |
| Dentistry and Oral Health |
0 |
0.07 |
| Medical Life |
0 |
0.07 |
| Obesity |
0 |
0.07 |